含(杂)芳磺酰基哌嗪的蛇床子素衍生物的合成及抗菌活性
Synthesis and Antibacterial Activities of Osthole Derivatives Containing(Hetero)arylsulfonylpiperazine
杨家强 1吴学姣 1卢子聪 1陈阳密 1佘慧娴 1刘讴灵1
作者信息
- 1. 遵义医科大学药学院,遵义 563000
- 折叠
摘要
设计合成了25个含(杂)芳磺酰基哌嗪的蛇床子素衍生物,经核磁共振波谱(1H NMR和13C NMR)及元素分析确证了其结构.抗菌活性测试结果表明,化合物4q对金黄色葡萄球菌(S.aureus)、大肠杆菌(E.coli)、耐甲氧西林金黄色葡萄球菌(MRSA)和耐氟喹诺酮大肠杆菌(FREC)的最小抑菌浓度(MIC)分别为0.5,1,2和2 µg/mL,化合物4s对S.aureus,E.coli,MRSA和FREC的MIC分别为0.25,0.5,1和2 µg/mL,化合物4u对S.aureus,E.coli,MRSA和FREC的MIC分别为0.5,2,1和4 µg/mL,3个化合物的抗S.aureu活性与对照药苯唑西林相似,且优于诺氟沙星;抗E.coli,MRSA和FREC活性优于对照药苯唑西林和诺氟沙星.研究结果表明,(杂)芳磺酰基哌嗪的引入能有效提高抗菌活性,扩大抗菌谱.
Abstract
In order to obtain antibacterial candidate compounds,the strategy of pharmacophore hybridisation was adopted to optimize the structure of the previously obtained active compound.Twenty-five osthole derivatives were designed and synthesized,and confirmed by means of nuclear magnetic resonance hydrogen spectroscopy(1H NMR),nuclear magnetic resonance carbon spectroscopy(13C NMR)and elemental analysis.The antibacterial activities against S.aureus,E.coli,methicillin-resistant S.aureus(MRSA)and fluoroquinolone-resistant E.coli(FREC)were evaluated,the results showed that the minimum inhibitory concentration(MIC)of compound 4q was 0.5,1,2,2 µg/mL respectively,the MIC of compound 4s was 0.25,0.5,1,2 µg/mL respectively,and the MIC of compound 4u was 0.5,2,1,4 µg/mL respectively.The inhibitory activities of these compounds against S.aureus were comparable to the control drug oxacillin,and superior to norfloxacin,and against E.coli,MRSA,and FREC were superior to the control drugs oxacillin and norfloxacin.The combination of(hetero)arylsulfonylpiperazine and osthole can effectively enhance antibacterial activities and expand the antibacterial spectrums.
关键词
蛇床子素衍生物/哌嗪/磺酰胺/抗菌活性Key words
Osthole derivative/Piperazine/Sulfonamide/Antibacterial activity引用本文复制引用
基金项目
贵州省科技计划项目(黔科合基础-ZK[2024]一般265)
国家级大学生创新创业训练计划项目(202310661006)
出版年
2024
国家科技期刊平台
NSTL
万方数据